biOasis Technologies (CVE:BTI) Receives Daily Media Sentiment Score of 0.20

Media headlines about biOasis Technologies (CVE:BTI) have trended neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than 6,000 news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. biOasis Technologies earned a daily sentiment score of 0.20 on their scale. InfoTrie also assigned news coverage about the company an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the immediate future.

BTI opened at C$0.32 on Friday. biOasis Technologies has a 12 month low of C$0.26 and a 12 month high of C$0.75. The firm has a market capitalization of $17.69 million and a P/E ratio of -3.68.

COPYRIGHT VIOLATION WARNING: “biOasis Technologies (CVE:BTI) Receives Daily Media Sentiment Score of 0.20” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2019/06/15/bioasis-technologies-cvebti-receives-daily-media-sentiment-score-of-0-20.html.

biOasis Technologies Company Profile

Bioasis Technologies Inc, a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company's lead program is xB3-001, an xB3 peptide vector-trastuzumab fusion. It is developing xB3, a proprietary platform technology for the delivery of therapeutics and imaging agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders in the areas of high unmet medical needs, including brain cancers, and metabolic and neurodegenerative diseases.

Read More: Why do analysts give a neutral rating?

Receive News & Ratings for biOasis Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biOasis Technologies and related companies with MarketBeat.com's FREE daily email newsletter.